Related Experiment Videos
Amiodarone pulmonary toxicity
Philippe Camus1, William J Martin, Edward C Rosenow
1Department of Pulmonary Medicine and Critical Care, Centre Hospitalier et Université de Bourgogne, F-2100 Dijon, France. phillipe.camus@chu-dijon.fr
Clinics in Chest Medicine
|April 6, 2004
Summary
Amiodarone pulmonary toxicity (APT) literature peaked decades ago but has resurged, indicating it remains a significant clinical issue. Early diagnosis and management of APT are crucial for patient outcomes.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Amiodarone pulmonary toxicity (APT) is a serious adverse effect of amiodarone therapy.
- Literature on APT peaked in the mid-1980s, with a subsequent decline, but has increased since the mid-1990s.
- This resurgence suggests APT remains a relevant clinical challenge.
Purpose of the Study:
- To highlight the persistent clinical relevance of amiodarone pulmonary toxicity.
- To underscore the diagnostic challenges associated with APT.
- To emphasize the variable outcomes in managing APT.
Main Methods:
- Literature review and analysis of publication trends related to amiodarone pulmonary toxicity.
- Synthesis of reported clinical cases and outcomes.
- Discussion of diagnostic difficulties and treatment efficacy.
Main Results:
- A significant peak in APT literature occurred in 1983-1984.
- Post-1990s publications indicate a renewed increase in reported APT cases.
- Noninvasive diagnosis of APT remains challenging.
- While many patients achieve good outcomes, some APT cases are refractory to treatment.
Conclusions:
- Amiodarone pulmonary toxicity continues to be an important clinical concern.
- Improved diagnostic strategies and management protocols for APT are needed.
- Ongoing vigilance and research are essential for optimizing patient care regarding amiodarone use.